$PIRS
Pieris Pharmaceuticals Inc

2017 Q3 Form 10-Q Financial Statement

#000119312517256092 Filed on August 11, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q2
Revenue $3.927M $1.853M $1.073M
YoY Change 400.25% 72.72% 569.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.850M $4.350M $2.370M
YoY Change 21.79% 83.54% 20.3%
% of Gross Profit
Research & Development $6.259M $5.396M $4.500M
YoY Change 35.42% 19.91% 160.79%
% of Gross Profit
Depreciation & Amortization $60.00K $110.0K -$10.00K
YoY Change -40.0% -1200.0% -114.29%
% of Gross Profit
Operating Expenses $9.111M $9.744M $6.868M
YoY Change 30.85% 41.87% 85.9%
Operating Profit -$5.184M -$7.891M -$5.795M
YoY Change -16.09% 36.16% 63.97%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$1.729M -$1.380M -$87.80K
YoY Change 9377.61% 1471.74% -2058.1%
Pretax Income -$6.913M -$9.271M -$5.883M
YoY Change 11.57% 57.58% 66.66%
Income Tax $146.0K $814.0K $0.00
% Of Pretax Income
Net Earnings -$7.059M -$10.09M -$5.883M
YoY Change 13.92% 71.42% 66.66%
Net Earnings / Revenue -179.76% -544.25% -548.37%
Basic Earnings Per Share
Diluted Earnings Per Share -$159.0K -$232.2K -$143.9K
COMMON SHARES
Basic Shares Outstanding 44.31M shares 43.07M shares 39.83M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $89.90M $50.30M $40.40M
YoY Change 145.63% 24.5% 304.0%
Cash & Equivalents $89.92M $50.32M $40.37M
Short-Term Investments
Other Short-Term Assets $2.800M $3.900M $3.500M
YoY Change -39.13% 11.43% 87.55%
Inventory
Prepaid Expenses
Receivables $2.537M $48.47M
Other Receivables $0.00 $0.00
Total Short-Term Assets $95.28M $102.7M $43.88M
YoY Change 131.61% 134.14% 247.11%
LONG-TERM ASSETS
Property, Plant & Equipment $3.456M $3.085M $2.447M
YoY Change 41.17% 26.08% 35.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $129.3K $128.2K $127.3K
YoY Change 1.29% 0.69%
Total Long-Term Assets $3.585M $3.213M $2.574M
YoY Change 39.2% 24.82% 40.22%
TOTAL ASSETS
Total Short-Term Assets $95.28M $102.7M $43.88M
Total Long-Term Assets $3.585M $3.213M $2.574M
Total Assets $98.86M $106.0M $46.45M
YoY Change 126.16% 128.09% 220.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.602M $4.646M $1.600M
YoY Change -42.18% 190.39% -23.81%
Accrued Expenses $5.100M $6.351M $2.325M
YoY Change 75.96% 173.11% 265.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.04M $35.80M $6.419M
YoY Change 292.27% 457.62% 112.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.46K $42.86K $42.06K
YoY Change -2.48% 1.9% -86.34%
Total Long-Term Liabilities $43.46K $42.86K $42.06K
YoY Change -2.48% 1.9% -86.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.04M $35.80M $6.419M
Total Long-Term Liabilities $43.46K $42.86K $42.06K
Total Liabilities $94.30M $96.62M $9.163M
YoY Change 671.06% 954.49% 175.14%
SHAREHOLDERS EQUITY
Retained Earnings -$127.8M -$120.7M -$89.91M
YoY Change 32.98% 34.29% 23.09%
Common Stock $134.8M $132.2M $128.5M
YoY Change 4.6% 2.83% 436622.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.558M $9.334M $37.29M
YoY Change
Total Liabilities & Shareholders Equity $98.86M $106.0M $46.45M
YoY Change 126.16% 128.09% 220.87%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$7.059M -$10.09M -$5.883M
YoY Change 13.92% 71.42% 66.66%
Depreciation, Depletion And Amortization $60.00K $110.0K -$10.00K
YoY Change -40.0% -1200.0% -114.29%
Cash From Operating Activities $35.20M -$6.520M -$6.110M
YoY Change -1083.24% 6.71% 106.42%
INVESTING ACTIVITIES
Capital Expenditures -$290.0K -$670.0K -$50.00K
YoY Change 45.0% 1240.0% 66.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00K
YoY Change
Cash From Investing Activities -$290.0K -$660.0K -$50.00K
YoY Change 45.0% 1220.0% 66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.030M 1.460M 15.28M
YoY Change -3483.33% -90.45% -9088.24%
NET CHANGE
Cash From Operating Activities 35.20M -6.520M -6.110M
Cash From Investing Activities -290.0K -660.0K -50.00K
Cash From Financing Activities 2.030M 1.460M 15.28M
Net Change In Cash 36.94M -5.720M 9.120M
YoY Change -1061.98% -162.72% -388.61%
FREE CASH FLOW
Cash From Operating Activities $35.20M -$6.520M -$6.110M
Capital Expenditures -$290.0K -$670.0K -$50.00K
Free Cash Flow $35.49M -$5.850M -$6.060M
YoY Change -1150.0% -3.47% 106.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44308775 shares
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40374433
CY2016Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.015
CY2017Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
899651
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6350841
CY2017Q2 us-gaap Assets Current
AssetsCurrent
102743499
CY2017Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
48470309
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3093303
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
132125992
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4646270
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2092523
CY2017Q2 us-gaap Assets
Assets
105956773
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50325193
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43840909 shares
CY2017Q2 us-gaap Cash
Cash
50325193
CY2017Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43840909 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
43841
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24798649
CY2017Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2017Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
60784291
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1123913
CY2017Q2 us-gaap Liabilities
Liabilities
96622913
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105956773
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
35795760
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
171880
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3085063
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128211
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42862
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
4963 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3947997
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4963 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4963 shares
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120743455
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
9333860
CY2017Q2 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
218264
CY2017Q2 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6350841
CY2017Q2 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
843830
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29349124
CY2016Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3719457
CY2016Q4 us-gaap Assets Current
AssetsCurrent
32672613
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57582
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
867969
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129349768
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2386183
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1501452
CY2016Q4 us-gaap Assets
Assets
35062831
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29355528
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43058827 shares
CY2016Q4 us-gaap Cash
Cash
29355528
CY2016Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43058827 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
43059
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2274514
CY2016Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1409483
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1198448
CY2016Q4 us-gaap Liabilities
Liabilities
9836304
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35062831
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8380154
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157788
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125741
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46667
CY2016Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1040321
dei Amendment Flag
AmendmentFlag
false
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
4963 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3259503
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4963 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4963 shares
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2264477
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102664853
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
25226527
CY2016Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
454931
CY2016Q4 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3719457
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1312070
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20969665
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18669672
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation
Depreciation
213378
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0471 pure
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1096594
dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001583648
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-23462
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8337459
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17264891
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
19250547
us-gaap Operating Expenses
OperatingExpenses
19093139
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1464936
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
78386937
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
46485468
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
813710
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1986896
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2332924
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
441051
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
167
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-842412
us-gaap Net Income Loss
NetIncomeLoss
-18078601
us-gaap Operating Income Loss
OperatingIncomeLoss
-15896981
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-591071
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-591071
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1368077
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
853110
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10698
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
177950
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1286986
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10755680
us-gaap Revenue Recognition Milestone Method Milestone
RevenueRecognitionMilestoneMethodMilestone
Pieris aggregates milestones into four categories: (i) research milestones, (ii) development milestones, (iii) commercial milestones and (iv) sales milestones.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7509 pure
us-gaap Revenues
Revenues
3196158
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap Share Based Compensation
ShareBasedCompensation
1312070
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7889 pure
dei Trading Symbol
TradingSymbol
PIRS
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43236701 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
1.87 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
2.16 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues, and expenses in the financial statements and disclosures in the accompanying notes. Significant estimates are used for, but are not limited to, revenue recognition, deferred tax assets, liabilities and valuation allowances, fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments and assumptions.</p> </div>
pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
19337
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
980229
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11025309
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10097507
us-gaap Depreciation
Depreciation
82757
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-47401
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4336100
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10044307
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5111418
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
350542
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
580908
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1144900
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-124608
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4083354
us-gaap Operating Expenses
OperatingExpenses
12495632
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15280672
us-gaap Net Income Loss
NetIncomeLoss
-10044307
us-gaap Operating Income Loss
OperatingIncomeLoss
-10176126
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-53200
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-53200
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
131819
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
124608
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8159532
us-gaap Revenues
Revenues
2319506
us-gaap Share Based Compensation
ShareBasedCompensation
980228
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7600 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7512 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
1.13 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
1.61 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40347816 shares
pirs Proceeds From Issuance Of Common And Preferred Stock
ProceedsFromIssuanceOfCommonAndPreferredStock
15280672
pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
207068
CY2016Q2 us-gaap Partners Capital Account Units Sold In Private Placement
PartnersCapitalAccountUnitsSoldInPrivatePlacement
8188804 shares
CY2016Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
16500000
CY2016Q2 pirs Proceeds From Issuance Of Private Placement Net
ProceedsFromIssuanceOfPrivatePlacementNet
15300000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
611845
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5777041
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2368217
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5883253
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
6868314
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-5883253
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5795452
CY2016Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
106212
CY2016Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
106212
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87801
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4500097
CY2016Q2 us-gaap Revenues
Revenues
1072862
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7512 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
1.13 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
1.87 pure
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.08
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.09
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
1.49 pure
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40862608 shares
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
559878
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10726772
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2017Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0471 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7553 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4348579
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9271157
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
813710
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
67
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
9744303
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-10084867
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7891445
CY2017Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-641905
CY2017Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-641905
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1379779
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5395724
CY2017Q2 us-gaap Revenues
Revenues
1852858
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7889 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7513 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
1.99 pure
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43407712 shares

Files In Submission

Name View Source Status
0001193125-17-256092-index-headers.html Edgar Link pending
0001193125-17-256092-index.html Edgar Link pending
0001193125-17-256092.txt Edgar Link pending
0001193125-17-256092-xbrl.zip Edgar Link pending
d404421d10q.htm Edgar Link pending
d404421dex101.htm Edgar Link pending
d404421dex102.htm Edgar Link pending
d404421dex103.htm Edgar Link pending
d404421dex104.htm Edgar Link pending
d404421dex105.htm Edgar Link pending
d404421dex311.htm Edgar Link pending
d404421dex312.htm Edgar Link pending
d404421dex321.htm Edgar Link pending
d404421dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pirs-20170630.xml Edgar Link completed
pirs-20170630.xsd Edgar Link pending
pirs-20170630_cal.xml Edgar Link unprocessable
pirs-20170630_def.xml Edgar Link unprocessable
pirs-20170630_lab.xml Edgar Link unprocessable
pirs-20170630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending